Skip to content

Randomized controlled trial for high-dose dual therapy versus bismuth quadruple therapy in the treatment of Helicobacter pylori in elderly patients

Randomized controlled trial for high-dose dual therapy versus bismuth quadruple therapy in the treatment of Helicobacter pylori in elderly patients

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000029679
Enrollment
Unknown
Registered
2020-02-09
Start date
2020-03-01
Completion date
Unknown
Last updated
2020-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

H. pylori infection eradication

Interventions

Control group:Standard bismuth quadruple therapy

Sponsors

The First Affiliated Hospital of Nanchang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged> 60 years; 2. Hp-positive patients who need Hp eradication treatment; 3. The pathological results of gastric mucosa biopsy suggest a positive result, or a 13-carbon urea breath test; 4. No previous Hp eradication treatment; 5. Voluntarily participate and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1) refuse to join the group; 2) The standard H. pylori eradication treatment has been performed before enrollment; 3) Those who have used antibiotics, bismuth before 4 weeks of treatment or H2RA and PPI before 2 weeks of treatment; 4) Gastric examination reveals gastric cancer; 5) Severe drinking (the daily alcohol intake exceeds 50G for more than 6 months); 6) Patients with severe primary diseases of liver, kidney, heart, brain, lung, endocrine system and hematopoietic system cannot be effectively controlled; 7) Clinically significant liver and kidney dysfunction (transaminase is greater than 1.5 times the upper limit of normal value, or blood creatinine is greater than the upper limit of normal value) or liver disease, anemia (hemoglobin <90g/L); 8) Those who are allergic to the drugs used in this research;

Design outcomes

Primary

MeasureTime frame
Carbon 13 expiratory value;

Countries

China

Contacts

Public ContactYin Zhu

The First Affiliated Hospital of Nanchang University

zhuyin27@sina.com.cn+86 13970841464

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026